Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Nantes University Hospital
With
Abbott
Ministry of Health, France
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Primary Mitral Regurgitation grade 3+ or 4+
Patients in class II to IV NYHA
Mitral valve anatomy appropriate to MitraClip® therapy and mitral valve surgery
Adult patients judged eligible for mitral valve surgery by the local heart team but at high surgical risk defined as: age ≥ 75 years and STS score ≥ 6 % or one frailty index or one major organ system compromise or one possible procedure-specific impediment (using MVARC definitions) ; or age \< 75 years and STS score \> 8 % or at least one other high-risk criterion following the MVARC definitions; or age \> 80 years and judged at high risk for surgery by the local heart team
Isolated Mitral valve pathology
If revascularization procedures are required, they must be performed more than 30 days from intervention (D0)
Patients affiliate to social security
Life expectancy \< 1 year due to non-cardiac conditions
Secondary Mitral regurgitation
Evolving endocarditis or active endocarditis or inflammatory disease in the last 3 months
Patient who cannot tolerate procedural anticoagulation or post procedural antiplatelet regimen
Rheumatic mitral valve disease
Evidence of intracardiac, inferior vena cava or femoral venous thrombus
Valve anatomy not compatible with MitraClip® implantation (cf. colum 3 table 3 page 57)
Stroke or transient ischaemic event within 30 days before D0
Modified Rankin Scale ≥4 disability (appendix 9)
TAVR within 30 days before D0-Untreated, clinically significant coronary artery disease requiring revascularization
Any percutaneous cardiovascular intervention within 30 days before D0 including ATC
Cardiovascular surgery, or carotid surgery within 30 days before D0
Any prior mitral valve surgery or transcatheter mitral valve procedure
Need for any concomitant cardiac surgery including treatment of severe secondary tricuspid regurgitation in accordance with class I recommendation in 2017 ESC guidelines. Surgical treatment of mild or moderate secondary tricuspid regurgitation (Class IIa and IIb recommendations) can still be performed in the protocol according to the local heart team decison
NYHA functional class I
LVEF \< 30%
Primary MR grade 1 to 2
Subjects in whom transesophageal echocardiography or transseptal catheterization are contraindicated or high-risk
Any condition preventing the patient from completing all protocol procedures (including compliance with guidelines directed medical therapy) and follow-up visits
Patient unable or unwilling to provide written, informed consent before study enrolment
Pregnant or nursing women
Vulnerable people: persons deprived of liberty; under trusteeship or under curatorship
Participation in another trial that would interfere with this trial